Clinical trial
Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With…
NCT00488436 · PETHEMA Foundation, Other · Completed
Key facts
| NCT number | NCT00488436 |
|---|---|
| Title | Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome |
| Official title | SMD/ATG-CSA: Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome |
| Lead sponsor | PETHEMA Foundation, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | Antithymocyte globulin, Cyclosporine |
| Enrollment | 25 |
| Start date | May 1, 2002 |
| Primary completion | Jun 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Jun 20, 2007 |
| Last update posted | Nov 19, 2008 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: